GlaxoSmithKline has dropped plans to sell part of its HIV drugs unit and promised to hold its dividend steady for the next three years as the struggling UK pharmaceuticals group set out its strategy to revive growth.
葛蘭素史克(GlaxoSmithKline，簡稱GSK)已放棄了轉讓部分艾滋病(HIV)藥物部門的計劃，并承諾要在今后三年內保證其穩定分紅。這家深陷困境的英國制藥集團正要著手實施其重獲增長的戰略。
您已閱讀7%（314字），剩余93%（4516字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。